Jonathan Michael Collins, MD | |
1 Hospital Dr, Columbia, MO 65212-0001 | |
(573) 882-9072 | |
(573) 884-4892 |
Full Name | Jonathan Michael Collins |
---|---|
Gender | Male |
Speciality | Critical Care (intensivists) |
Experience | 18 Years |
Location | 1 Hospital Dr, Columbia, Missouri |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659473510 | NPI | - | NPPES |
Facility Name | Location | Facility Type |
---|---|---|
University Of Missouri Health Care | Columbia, MO | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
The Curators Of The University Of Missouri | 4486759560 | 959 |
News Archive
Research on the fungus that ranks as one cause of dandruff - the embarrassing nuisance that, by some accounts, afflicts half of humanity - is pointing scientists toward a much-needed new treatment for the condition's flaking and itching.
Genetics may play a role in determining whether patients experience chronic pain after surgery, suggests a study published today in the Online First edition of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists
CoAxia Inc. of Maple Grove, MN, announced today that the results of the SENTIS clinical trial a worldwide, multi-center, randomized study of its NeuroFlo catheter were presented on Saturday, October 16th, by SENTIS Principal Investigator, Professor Ashfaq Shuaib at the 2010 World Stroke Congress in Seoul, South Korea.
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
› Verified 7 days ago
Entity Name | The Curators Of The University Of Missouri |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1235126921 PECOS PAC ID: 4486759560 Enrollment ID: O20070418000290 |
News Archive
Research on the fungus that ranks as one cause of dandruff - the embarrassing nuisance that, by some accounts, afflicts half of humanity - is pointing scientists toward a much-needed new treatment for the condition's flaking and itching.
Genetics may play a role in determining whether patients experience chronic pain after surgery, suggests a study published today in the Online First edition of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists
CoAxia Inc. of Maple Grove, MN, announced today that the results of the SENTIS clinical trial a worldwide, multi-center, randomized study of its NeuroFlo catheter were presented on Saturday, October 16th, by SENTIS Principal Investigator, Professor Ashfaq Shuaib at the 2010 World Stroke Congress in Seoul, South Korea.
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Jonathan Michael Collins, MD Po Box 843966, Kansas City, MO 64184-3966 Ph: (573) 884-3300 | Jonathan Michael Collins, MD 1 Hospital Dr, Columbia, MO 65212-0001 Ph: (573) 882-9072 |
News Archive
Research on the fungus that ranks as one cause of dandruff - the embarrassing nuisance that, by some accounts, afflicts half of humanity - is pointing scientists toward a much-needed new treatment for the condition's flaking and itching.
Genetics may play a role in determining whether patients experience chronic pain after surgery, suggests a study published today in the Online First edition of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists
CoAxia Inc. of Maple Grove, MN, announced today that the results of the SENTIS clinical trial a worldwide, multi-center, randomized study of its NeuroFlo catheter were presented on Saturday, October 16th, by SENTIS Principal Investigator, Professor Ashfaq Shuaib at the 2010 World Stroke Congress in Seoul, South Korea.
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
› Verified 7 days ago
Dr. Rahul Jain, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-2296 Fax: 573-884-7743 | |
Mr. Ghulam Ghous, M.D Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-9066 Fax: 573-884-3037 | |
Gregory Gaskey, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-9066 Fax: 573-884-3037 | |
Christos N Papageorgiou, M.D., PHD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: One Hospital Drive, Columbia, MO 65212 Phone: 573-882-2100 Fax: 573-884-7822 | |
Jack Bragg, DO Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 101 S Fairview Road, Columbia, MO 65201 Phone: 573-884-7600 Fax: 573-884-8200 | |
Michelle Middleton Woodson, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 Fax: 573-814-6584 | |
Dr. Sameer Bellapravalu, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Drive Room 313, Psychiatry Dept Dc067.00, Columbia, MO 65212 Phone: 573-884-6136 Fax: 573-884-1070 |